Provista Diagnostics

About Provista Diagnostics

Provista Diagnostics, Inc. operates as a molecular diagnostics company with a focus on developing and commercializing blood-based tests for women's cancers. Founded in 2007, the company has centered its efforts on addressing unmet clinical needs in oncology, particularly for breast and gynecologic malignancies. The company's history involves significant corporate transitions, including an acquisition by Ascenda BioSciences in June 2019 and a subsequent acquisition by Todos Medical in a deal finalized in April 2021 for $7.5 million in cash and stock. This final acquisition positioned Provista as the U.S. base for all of Todos Medical's operational activities, including diagnostic tests for cancer, COVID-19, and Alzheimer's disease.

The company's principal offering is Videssa® Breast, a proteomic blood test designed to provide clarity for physicians when mammogram results are inconclusive or difficult to interpret, especially in women with dense breast tissue. This test analyzes multiple protein biomarkers and tumor-associated autoantibodies in a blood sample to detect the presence or absence of breast cancer. The primary benefit of Videssa Breast is its potential to reduce the number of false positives from imaging and subsequently decrease the reliance on invasive follow-up procedures like biopsies by up to 67%. With a high negative predictive value of over 99%, the test offers clinicians a tool to confidently rule out breast cancer and provide patients with greater peace of mind. The test is performed in Provista's CLIA-certified and CAP-accredited high-complexity clinical laboratory.

Provista Diagnostics' business model is rooted in providing advanced diagnostic testing services to clinicians and healthcare systems. Following its acquisition by Todos Medical, the company's laboratory capabilities were expanded to include COVID-19 PCR testing, respiratory testing, and other diagnostic services, serving clients in the medical and entertainment industries. The strategy involves leveraging the existing lab infrastructure, which includes PCR and ELISA capabilities, to commercialize a suite of diagnostic tests. This includes not only the relaunch of Videssa Breast but also the development and deployment of tests for other conditions, thereby creating a comprehensive diagnostic solutions provider.